|Bid||71.25 x 900|
|Ask||71.70 x 1200|
|Day's range||71.09 - 72.18|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||297.42|
|Forward dividend & yield||2.84 (3.96%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||N/A|
FOSTER CITY, Calif., September 22, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. This late-breaking data will be presented at the IDWeek 2021 virtual conference.
FOSTER CITY, Calif., September 20, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the virtual IDWeek 2021 conference, taking place September 29 – October 3. The findings in COVID-19 research, HIV treatment research and HIV prevention research are the latest example of Gilead’s ongoing commitment to help address the evolving COVID-19 pandemic and the needs of people affected by HIV.
FOSTER CITY, Calif., September 16, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In a retrospective subgroup analysis, Trodelvy improved progression-free survival (PFS), overall survival (OS) and objective response